FDA Clears MagStim’s Horizon Performance Platform

May 20, 2019

MagStim has earned the FDA’s go-ahead for its Horizon Performance platform, a device used to treat patients with depression through magnetic pulse therapy.

By using transcranial magnetic stimulation, the device allows patients to avoid the side effects of drugs and invasive treatments.

The platform has been used in situations where antidepressant treatments are ineffective and before therapies such as electroconvulsive therapy are considered.


View today's stories